<?xml version="1.0" encoding="UTF-8"?>
<p>Markers of hypercoagulability and higher inflammatory mediators are consistently associated with worse outcomes in patients with ARDS and sepsis. These observations have led to numerous clinical trials targeting various components of inflammatory and coagulation pathways in acute lung injury, ARDS or sepsis. Studies with heparin, steroids, non-steroidal anti-inflammatory drugs, and TNF-α inhibitors have been disappointing.
 <sup>
  <xref rid="bibr95-1358863X20932640" ref-type="bibr">95</xref>
  <xref rid="bibr96-1358863X20932640" ref-type="bibr"/>
  <xref rid="bibr97-1358863X20932640" ref-type="bibr"/>
  <xref rid="bibr98-1358863X20932640" ref-type="bibr"/>
  <xref rid="bibr99-1358863X20932640" ref-type="bibr"/>–
  <xref rid="bibr100-1358863X20932640" ref-type="bibr">100</xref>
 </sup>
</p>
